RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 Higher Incremental Cost-Effectiveness Ratios Seen with Biologics in the TEAR Trial
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 18
SP 18
OP 19
DO 10.1177/155989771318009
UL http://mdc.sagepub.com/content/13/18/18.abstract
AB As additional treatments have been approved for rheumatoid arthritis (RA), researchers have used clinical trial data to analyze the cost effectiveness of these new drugs. Since 1998, more than 30 cost-effectiveness analyses (CEAs) have been conducted, with highly variable results. This article presents the CEA results of patient-level data from the Treatment of Early Aggressive Rheumatoid Arthritis trial [TEAR; NCT00259610], a large, randomized, double-blind clinical study.